**CONTACT INFORMATION**

Dr Pawan Saharan

www.biomix.in

drpawan@biomix.in

+91 8291084108 (WA mobile)

**Estimated Value:**

* US$ 5.6 billion

 per IPSOS market research

**Est timeline to market:**

* 3 to 6 months after funding

**Market Range:**

* Phase 1: North America, India & Middle East
* Phase 2: Europe, Russia & Australia

**Net Assets:**

* IP- Global 58 therapeutic product patents in US, CA, UK, EU, Africa & Asia
* Global Clinical Efficacy & Safety studies conducted on 25000+ humans for 12 years 100% EFFICACY & Safety Studies Regulatory filling and registration in select nations
* Functional Pilot Plant to supply to Govt of India under National Health Program, Govt of India

**Capabilities:**

* International reach

**Financial Information Seeking:**

* Seeking US$ 60 million

 (40 for North America, 20

 for India)

**Use of funds:**

* Global scale manufacturing

Facilities in US & India, IP & Tech Transfer

**Target Customer:**

* Family Projects
* Legacy Projects
* 10% quarterly dividends

 or

* 15% preferred

**EXECUTIVE SUMMARY**

**OVERVIEW**

Our goal is to help billions of people worldwide via safe, affordable & effective treatment & prevention of all communicable diseases such as Wuhan Virus Covid-19 pandemic. Our clinically proven, broad spectrum, anti-viral immunomodulator is globally tested with 100% efficacy & safety for 12 years on 25000+ humans.

The productconsists of a patented new molecule of submicroscopic nonapeptides which have been isolated from bovine colostrum via patented Ultra Nano filtration Technology for first time.

Our Vision: What causes illness and how to reach solutions in providing healthcare in every nook and corner of the universe via our Immunity Product, proprietary telemedicine & Lab on Chip for mass screening with emergency health alerts.

**STRATEGY**

Bringing the Product to the Markets in North America, Middle Est and Asia to begin with and export to UK, EU, RUSSIA, AUS from these counties with a differentiator from other COVID treatments/vaccines offered by GiLead, Pfizer, Moderna, Oxford Astra Zeneca, Sputnik & India under temporary FDA approvals which can be withdrawn.

**MARKET PROBLEMS**

Global pandemics like Wuhan COVID-19, Bird Flu, Swine Flu, HIV & chronic immunity disorders. People with weak immunity are at higher risk of getting severely sick from Covid-19.

**SOLUTION**

Our product made from mother’s 1st milk /bovine colostrum has nano informational peptides that help people lead longer & healthier lives by naturally building the body’s own immune system, aiding in prevention & cure of all communicable & immunity diseases along with sustainable malnutrition eradication for bottom of the pyramid segment globally.

**OPPORTUNITY**

We propose to use 21st Century Nanotechnology Innovation in improving health and wellbeing of 8 billion people by marketing & distribution of 8 different formulations viz. oral gargle, MMS, powder & liquid sachets.

Opportunity for family funds via legacy projects, 10% quarterly dividends or 15% preferred shareholding along with exit via Nasdaq, LSE & Bombay Stock Exchange listings.

Projected revenue US$ 1.45 billion globally with PAT EBITDA US$ 566 million, based on real time market research conducted at US$2mn cost by IPSOS USA by Glaxo on 800 families from India, UK & USA with ITP score of 97-100% for two concepts that respondents liked and were ready to pay for our Product, both on standalone basis & as an additive.

Published Ref: <https://patents.google.com/patent/US9249188B2/en>.

<http://medicaltraveltoday.com/spotlight-interview-pawan-saharan-founder-ceo-biomix-network-inc/>

<https://escientificpublishers.com/receptol-oral-spray-shield-for-coronavirus-proposed-treatment-prevention-as-demonstrated-in-aids-JBI-02-0007>